Ocata Therapeutics

Ocata Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of regenerative ophthalmic therapies. Ocata's most advanced products are currently in clinical trials for the treatment of Stargardt's macular degeneration, dry age-related macular degeneration, and myopic macular degeneration. Ocata's intellectual property portfolio includes a pluripotent stem cell platform - hESC and induced pluripotent stem cells (iPSC) - as well as other cell therapy research programs.